ESTEFANIA
CERRO HERREROS
INVEST CONT VALi+d
M BEATRIZ
LLAMUSI TROISI
INVEST DOCT UV SENIOR
Publications dans lesquelles il/elle collabore avec M BEATRIZ LLAMUSI TROISI (13)
2024
-
AntimiR treatment corrects myotonic dystrophy primary cell defects across several CTG repeat expansions with a dual mechanism of action
Science advances, Vol. 10, Núm. 41, pp. eadn6525
2023
-
BlockmiR AONs as Site-Specific Therapeutic MBNL Modulation in Myotonic Dystrophy 2D and 3D Muscle Cells and HSALR Mice
Pharmaceutics, Vol. 15, Núm. 4
-
Peptide-conjugated antimiRs improve myotonic dystrophy type 1 phenotypes by promoting endogenous MBNL1 expression
Molecular Therapy - Nucleic Acids, Vol. 34
2022
-
Proof of concept of peptide-linked blockmiR-induced MBNL functional rescue in myotonic dystrophy type 1 mouse model
Molecular Therapy - Nucleic Acids, Vol. 27, pp. 1146-1155
2021
-
Preclinical characterization of antagomiR-218 as a potential treatment for myotonic dystrophy
Molecular Therapy - Nucleic Acids, Vol. 26, pp. 174-191
2020
-
Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy
Molecular Therapy - Nucleic Acids, Vol. 21, pp. 837-849
2018
-
MiR-23b and miR-218 silencing increase Muscleblind-like expression and alleviate myotonic dystrophy phenotypes in mammalian models
Nature Communications, Vol. 9, Núm. 1
-
RNA-mediated therapies in myotonic dystrophy
Drug Discovery Today, Vol. 23, Núm. 12, pp. 2013-2022
-
RbFOX1/MBNL1 competition for CCUG RNA repeats binding contributes to myotonic dystrophy type 1/type 2 differences
Nature Communications, Vol. 9, Núm. 1
2017
2016
2015
-
Increased autophagy and apoptosis contribute to muscle atrophy in a myotonic dystrophy type 1 Drosophila model
DMM Disease Models and Mechanisms, Vol. 8, Núm. 7, pp. 679-690